Cetuximab
≥95%
- Product Code: 103539
CAS:
205923-56-4
| Molecular Weight: | Molecular Formula: | ||
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃, away from light |
Product Description:
Cetuximab is primarily used in the treatment of certain types of cancer, particularly metastatic colorectal cancer and squamous cell carcinoma of the head and neck. It works by targeting and inhibiting the epidermal growth factor receptor (EGFR), which is often overexpressed in these cancers, thereby slowing tumor growth and spread.
In colorectal cancer, it is typically administered in combination with chemotherapy for patients whose tumors express the EGFR and do not have mutations in the KRAS gene. This targeted approach helps improve the effectiveness of the treatment while minimizing damage to normal cells.
For head and neck cancer, cetuximab is often used alongside radiation therapy, especially in cases where the cancer is locally advanced. This combination has been shown to enhance the efficacy of radiation, improving survival rates and controlling the progression of the disease.
Additionally, cetuximab is sometimes used as a monotherapy for patients who cannot tolerate traditional chemotherapy or radiation, offering a valuable alternative for managing their condition. Its ability to specifically target cancer cells makes it a crucial component in personalized cancer treatment strategies.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | Colorless To Light Yellow Liquid |
| Purity (%) | 95-100 |
| Infrared Spectrum | Conforms To Structure |
| Concentration | 4.5mg/ml-5.5mg/ml |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.001 | 10-20 days | €490.18 |
+
-
|
| 0.005 | 10-20 days | €1,035.76 |
+
-
|
| 0.025 | 10-20 days | €3,107.80 |
+
-
|
Cetuximab
Cetuximab is primarily used in the treatment of certain types of cancer, particularly metastatic colorectal cancer and squamous cell carcinoma of the head and neck. It works by targeting and inhibiting the epidermal growth factor receptor (EGFR), which is often overexpressed in these cancers, thereby slowing tumor growth and spread.
In colorectal cancer, it is typically administered in combination with chemotherapy for patients whose tumors express the EGFR and do not have mutations in the KRAS gene. This targeted approach helps improve the effectiveness of the treatment while minimizing damage to normal cells.
For head and neck cancer, cetuximab is often used alongside radiation therapy, especially in cases where the cancer is locally advanced. This combination has been shown to enhance the efficacy of radiation, improving survival rates and controlling the progression of the disease.
Additionally, cetuximab is sometimes used as a monotherapy for patients who cannot tolerate traditional chemotherapy or radiation, offering a valuable alternative for managing their condition. Its ability to specifically target cancer cells makes it a crucial component in personalized cancer treatment strategies.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
€0.00
€0.00
Total :